Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 19/20 | 0.71 |
| ▸ | CRBN | Q96SW2 | 19/20 | 0.71 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.64 |
| ▸ | TNF | P01375 | 1/20 | 0.64 |
| ▸ | IL1B | P01584 | 1/20 | 0.64 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.64 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22291958 | 0.89 | DDB1 (0.57) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL19551164 | 0.89 | DDB1 (0.70) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL23168704 | 0.89 | DDB1 (0.77) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL29569352 | 0.88 | DDB1 (0.69) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL14085580 | 0.86 | DDB1 (0.75) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL3534002 | 0.86 | DDB1 (0.77) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL21304403 | 0.86 | DDB1 (0.77) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL19481530 | 0.86 | DDB1 (0.83) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL28687508 | 0.86 | DDB1 (0.69) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL28406462 | 0.86 | DDB1 (0.70) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200113896-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | SIGNAL PHARM LLC (US) | 2020-04-16 | — | — | US | disclosed |
| US-10385037-B2 | 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2019-08-20 | — | — | US | disclosed |
| US-20180155316-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2018-06-07 | — | — | US | disclosed |
| US-9920027-B2 | 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2018-03-20 | — | — | US | disclosed |
| US-RE46639-E1 | 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2017-12-19 | — | — | US | disclosed |
| US-20160024048-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2016-01-28 | — | — | US | disclosed |
| US-9181216-B2 | 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140314752-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140309436-A1 | THALIDOMIDE ANALOGS | P2D, INC. | 2014-10-16 | — | — | US | disclosed |
| US-20140309436-A1 | THALIDOMIDE ANALOGS | P2D, INC. | 2014-10-16 | — | — | US | disclosed |
| US-20130035363-A1 | Thalidomide Analogs | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2013-02-07 | — | — | US | disclosed |
| US-20110245210-A1 | THALIDOMIDE ANALOGS | The Government of the United States of America, as represented by the Secretary of | 2011-10-06 | — | — | US | disclosed |
| US-20110245210-A1 | THALIDOMIDE ANALOGS | The Government of the United States of America, as represented by the Secretary of | 2011-10-06 | — | — | US | disclosed |
| US-20110245210-A1 | THALIDOMIDE ANALOGS | The Government of the United States of America, as represented by the Secretary of | 2011-10-06 | — | — | US | disclosed |
| US-7973057-B2 | Thalidomide analogs | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973057-B2 | Thalidomide analogs | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973057-B2 | Thalidomide analogs | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-07-05 | — | — | US | disclosed |
| US-20060211728-A1 | Thalidomide analogs | P2D INC. | 2006-09-21 | — | — | US | disclosed |
| EP-1663223-A2 | THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005028436-A2 | THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035363-A1 | Thalidomide Analogs | TNF, TNFRSF1A, TNFRSF9 | DDB1 919/4885CRBN 241/4885IKZF3 949/4885 |
| US-20060211728-A1 | Thalidomide analogs | TNF, TNFRSF1A, PGF | DDB1 953/4885CRBN 321/4885IKZF3 854/4885 |
| US-20200113896-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | MTOR, ULK1, RICTOR | DDB1 820/4885CRBN 869/4885IKZF3 355/4885 |
| US-20140314752-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | MTOR, ULK1, RICTOR | DDB1 820/4885CRBN 869/4885IKZF3 355/4885 |
| US-20140309436-A1 | THALIDOMIDE ANALOGS | TNF, TNFRSF1A, TNFRSF9 | DDB1 919/4885CRBN 241/4885IKZF3 949/4885 |
| US-20160024048-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A4, CYP3A7, CYP4B1 | DDB1 2458/4885CRBN 3542/4885IKZF3 3179/4885 |
| US-20110245210-A1 | THALIDOMIDE ANALOGS | TNF, TNFRSF1A, PGF | DDB1 953/4885CRBN 321/4885IKZF3 854/4885 |
| US-20180155316-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A4, CYP3A7, CYP4B1 | DDB1 2458/4885CRBN 3542/4885IKZF3 3179/4885 |
| US-10385037-B2 | 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same | CYP3A4, CYP3A7, CYP4B1 | DDB1 2521/4885CRBN 3597/4885IKZF3 3137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.